A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy.

A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy. Abstract Text:

Spiridon Papapetropoulos,Jennifer Friedman,Craig Blackstone,Gary I Kleiner,Brian C Bowen,Carlos Singer,

X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disorder caused by a mutation in the Bruton agammaglobulinemia tyrosine kinase gene that results in severe B-cell deficiency. So far, neurological complications of XLA have been primarily related to acute and/or chronic central nervous system enteroviral infections. In the last few years a progressive neurodegenerative syndrome of unknown etiology has been described in XLA patients. We describe and present a video of an XLA patient who developed a fatal dementing, dystonia-Parkinsonism syndrome 14 years into his immune disorder. Physician awareness of this rare syndrome may lead to its better characterization and management.

A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy. Publishing Authors By Initials

S Papapetropoulos,J Friedman,C Blackstone,GI Kleiner,BC Bowen,C Singer,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Movement disorders : official journal of the Movem

VOLUME: 22

Page Numbers: 1664-6

Journal Abbreviation: Mov. Disord.

ISSN: 0885-3185

DAY: 15

MONTH: Aug

YEAR: 2007

A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8610688

A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy. Keywords Mesh Terms:

KEYWORDS: X-Linked Combined Immunodeficiency Disea

MESH TERMS: pathology

Chemical & Substance for Abstract: A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy. Information

Substance Name: Immunologic Factors

Registry Number: 0

Grant and Affiliation Information for A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy.

AFFILIATION: Department of Neurology, University of Miami, Miller School of Medicine, Miami, Florida 33136, and Massachusetts General Hospital, Boston, USA. spapapetropoulos@med.miami.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Mov Disord

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy Related Publications

• A longitudinal case study of a child with mosaic trisomy 22: language, cognitive, behavioral, physical, and dental outcomes.
• A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy.
• A recipe for randomness.
• Aggressive drug marketing tactics trigger backlash.
• Bupropion for smokers hospitalized with acute cardiovascular disease.
• Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma.
• Combinations of biomarkers predictive of later life mortality.
• Constitutive turnover of cyclin E by Cul3 maintains quiescence.
• Detection and Classification of Movements in Bed using Load Cells.
• Education correction using years in school or reading grade-level equivalent? Comparing the accuracy of two methods in diagnosing HIV-associated neurocognitive impairment.
• Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis.
• In vivo dynamics of RNA polymerase II transcription.
• Laryngeal dystonia as a presenting symptom of young-onset Parkinson's disease.
• Mast cell-mediated changes in smooth muscle contractility during mouse giardiasis.
• Metastasis to the submandibular gland in head and neck carcinomas.
• Norepinephrine transporter polymorphisms in Tourette syndrome with and without attention deficit hyperactivity disorder: no evidence for significant association.
• Postdischarge treatment costs following closure of a state geropsychiatric ward: comparison of 2 levels of community care.
• Prenatal cocaine and tobacco effects on children's language trajectories.
• Role of the brain-gut axis in alcohol-related gastrointestinal diseases--what can we learn from new animal models?
• Selective effects of cyclosporin A on colony-forming lymphoid and myeloid cells in man.
• Sleep and sleep disturbance: from genes to dreams.
• The Cullin3 ubiquitin ligase functions as a Nedd8-bound heterodimer.
• The aging experience of well elderly women: initial results.
• The headache doctor: the dog ate my pills and other tales of woe.
• The validity of the 2004 U.S. News & World Report's rankings of schools of social work: a response.
• Tic disorders: neural circuits, neurochemistry, and neuroimmunology.
• Tumour necrosis factor alpha contributes to protection against Giardia lamblia infection in mice.
• Within-trial contrast: pigeons prefer conditioned reinforcers that follow a relatively more rather than a less aversive event.
• [Ectopic prostatic tissue in the uterine cervix]
• [Meningothelial meningioma in a mature cystic teratoma of the ovary]